On the other hand, since tumor-related inflammation plays a vital role in the development and progression of cancers [35, 36], we should study the relationship between expression of CD39/CD73/A2AR and serum inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the monocyte-to-lymphocyte ratio (MLR), C-reactive protein, and the systemic immune-inflammation index (SII), or a systemic inflammation response index (SIRI). The gene discussed is ENTPD1; the disease is cancer.